Femasys Q1 sales rise on FemBloc demand

Femasys

08/05/2026 21:26

Overview

US fertility and birth control device maker's Q1 sales rose 24.5% yr/yr, led by FemBloc

Company posted net income after prior-year loss, aided by gains in fair value of instruments

Femasys advanced commercialization and expanded international partnerships during the quarter

Outlook

Company expects current cash resources to fund operations into the third quarter of 2026

Result Drivers

FEMBLOC SALES - Co said Q1 sales growth was primarily due to sales of FemBloc

COMMERCIALIZATION EFFORTS - Co advanced commercial adoption of FemaSeed Complete and expanded provider awareness and partnerships

LOWER R&D EXPENSES - Co reported decreased R&D expenses due to transition of products into inventory and lower development costs

Company press release: ID:nGNX5SDnWR

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
$0


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Femasys Inc is $4.50, about 902% above its May 7 closing price of $0.45

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)